Scandinavian Biopharma announces successful results in placebo-controlled Phase I study of an oral, inactivated vaccine against diarrhea for travelers and children in developing countries

May 22, 2013

Latest News

Scandinavian Biopharma, May 2013

Results from a clinical Phase I study of a novel vaccine against diarrhea caused by enterotoxigenic Escherichia coli (ETEC) found the vaccine was safe and well tolerated. ETEC is a common culprit of travelers' diarrhea, but it is also a major cause of diarrheal disease among children living in endemic countries. Future clinical studies will document the vaccine’s protective efficacy in travelers, and will study its safety and immunogenicity among children in ETEC-endemic areas.

Read the full press release.